Endotracheal Tube Versus Laryngeal Mask Airway for Esophagogastroduodenoscopy

• Study design The study will be randomized, controlled, and prospective in design.
• Comparison groups The two comparison groups will be:

• Laryngeal Mask Airway Group (LMA), N = 42 LMA will be used as the intraoperative airway device.
• Endotracheal Tube Group (ETT), N = 42 ETT will be used as the intraoperative airway device.
• Study and timeline of interventions

• Preoperative: All patients enrolled in this study will receive a standard preoperative dose of oral midazolam 0.5 mg/kg up to 15 mg, 15 to 30 minutes prior to anesthetic induction.
• Intraoperative: Subjects will all undergo induction of anesthesia by inhalation of sevoflurane and oxygen. An intravenous catheter (IV) will be placed, followed by lidocaine 2mg/kg IV. The airway device will be placed (LMA or ETT). As required for the procedure, the subject will be placed in a left lateral decubitus (left side down) position. Maintenance of anesthesia will be provided with sevoflurane at a concentration of 1.5-2 MAC, or higher if deemed appropriate for the clinical setting as judged by the anesthesiologist. All participants will be given the anti-nausea medicine ondansetron 0.1mg/kg (maximum 4 mg) after placement of the airway device. When the endoscope is removed at the completion of the procedure, the patient will be returned to the supine position. The sevoflurane will be discontinued and the airway device will be removed when the anesthesiologist deems it appropriate. Prior to leaving the OR, the anesthesiologist may give pain or anti-anxiety medicine as needed.
• Postoperative: All patients will receive routine PACU care. Pain and anxiety scores will be recorded according to routine PACU practice. Medication for pain, nausea, and anxiety will be given according to the judgment of the anesthesiologist.
• Measured end-points:

i. Time from induction of anesthesia to placement of the airway device ii. Time from end of procedure to arrival in the PACU iii. Time spent in the PACU iv. Overall time from arrival in the OR to discharge home v. Vomiting after the procedure vi. Nausea requiring medicine after the procedure vii. Lowest oxygen saturation level during or after the procedure viii. Highest concentration of sevoflurane during the procedure ix. Highest pain level after the procedure x. Amount of pain medicine given xi. Adverse events xii. Satisfaction level of the doctor doing the EGD

Inclusion criteria

• Age 3-17

• Scheduled for Esophagogastroduodenoscopy, with or without biopsies
• Have been informed of the nature of the study and informed consent has been obtained from the legally responsible
• Have provided assent in accordance with Institutional Review Board requirements
• Are able to complete pain assessment evaluations as determined by preoperative evaluations

Exclusion criteria

• • Abnormal/difficult airway

• Symptomatic obstructive sleep apnea
• Risk of aspiration of stomach contents
• Upper respiratory infection within last 14 days
• Allergy to lidocaine or ondansetron
• EGD procedures associated with the need to exclude ondansetron administration
• BMI >85th percentile for age
• Are unable to communicate effectively with study personnel
• Have a positive urine pregnancy test (menstruating females only at screening